Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

BEVERLY HILLS, California, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (NORD) (“Nordicus” or the “Company”), a financial consulting ...

This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using ...

Nanoform (Finland), an innovative nanoparticle medicine enabling company, today announced it has signed a GMP 1 manufacturing program (clinical development) to enhance TargTex’s Glioblastoma ...

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its ...

The partnership addressed complex peptide synthesis and purification challenges to achieve high yield and purity suitable for clinical use BEVERLY HILLS, California, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ...